Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
Conditions
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Locations
19
United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
UCLA Cancer Center
Santa Monica, California, United States
University Of Colorado
Aurora, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory University; Winship Cancer Institute
Atlanta, Georgia, United States
Start Date
April 20, 2017
Primary Completion Date
May 7, 2020
Completion Date
September 5, 2023
Last Updated
September 19, 2024
NCT06758401
NCT07431827
NCT06427941
NCT06476808
NCT07164313
NCT05142189
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions